The Administrators of the Tulane Educational Fund

Other

Biomeasure Incorporated

The Rockefeller University

Mcgill University

American Cyanamid Company

Auckland Uniservices Limited

Societe De Conseils De Recherches Et D'applications Scientifiques Sas

Tulane Educational Fund

The Ohio State University

Louisiana State University and Agricultural & Mechanical College

Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.)

Ipsen Pharma S.a.s.

Children's Hospital

Tulane University

David H Coy

Abba J Kastin

William A Murphy

Jacques-Pierre Moreau

John E Taylor

Sun H Kim

Andrew V Schally

Cyril Y Bowers

Simon J Hocart

Joseph A Fuselier

Barry A Morgan

Robert F Garry

Gloria S Tannenbaum

Jane A McKeating

Srikanta Dash

Walajapet G Rajeswaran

Eugene A Woltering

Ian Reginald Reid

Arthur E Bogden

Min Li

Lichun Sun

Jerome L Maderdrut

Zheng Xin Dong

Michael DeWitt Culler

Mark Louis Heiman

Jillian Cornish

Garth James Smith Cooper

George J Drouant

M Sue O'Dorisio

Thomas M O'Dorisio

Garth James Cooper

Chester A Meyers

Andrew V Shally

Vecihi Batuman

Wojciech J Rossowski

Lee A Henderson

Maria Chiara Zatelli

Jane A Mckeating

Ettore Ciro Degli Uberti

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.

Conjugates, their compositions, and their related methods

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) including but not limited to conjugates comprising FK-506 and ascomycin. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating. Further embodiments include methods for making the inventive compound. Additional embodiments of the invention are also discussed herein.

Conjugates, their compositions, their uses, and their methods of making

The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A-A-A-Gly-Ser-A-Phe-Leu-A-A-A-A, wherein each of A, A, and Ais independently absent, an amino acid, or an amino protecting group; each of A, A, A, and Ais independently absent or an amino acid; and Ais a serine conjugated with a &#x2014;C(O)C-Calky or a diaminopropionic acid conjugated with a &#x2014;C(O)C-Calkyl group, provided that at least one of A, A, or Ais present.

Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof

Multicomponent compositions and methods of use thereof are disclosed herein. Some embodiments of the present invention include multicomponent compositions comprising a first component and a second component, where the first component comprises a notch influencing molecule and the second component comprises a GPCR targeted molecule. Kits comprising the multicomponent composition are also disclosed. Methods for providing the multicomponent composition to one or more cells are additionally provided. Further embodiments include methods of using the multicomponent composition such as, for example, methods of administering the multicomponent composition and method of treating organisms (such as mammals) using the multicomponent composition.

Multicomponent compositions and their uses

Featured are methods and compositions for treating, managing, preventing, or reducing injury to the kidney of a mammal (e.g., a human) caused by one or more iodinated radiocontrast media. The methods include administering an effective amount of one or more pituitary adenylate cyclase-activating polypeptide (PACAP)-like compounds, which includes native human PACAP38, native human PACAP27, native human vasoactive intestinal peptide (VIP), their agonists, analogs, fragments, and derivatives, with activities toward one or more of the PACAP/VIP receptors, including all of their various isoforms. Also provided are pharmaceutical compositions of one or more PACAP-like compounds, either alone or in combination with one or more other prophylactic/therapeutic agents useful for treating, managing, or preventing injury to the kidney of a mammal (e.g., a human) undergoing treatment with one or more iodinated radiocontrast media. Also featured is an in vivo mouse model for testing the efficacy of cytoprotective agents against contrast-induced nephropathy.

Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy

The present invention provides novel peptides that can modulate the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and sub-types, isoforms and variants thereof). These peptides are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperpro-liferative disorders.

Growth hormone secretatogue receptor antagonists and uses thereof

The present invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist. A somatostatin receptor antagonist having the formula Cpa-cyclo(D-Cys-4-Pal-D-Trp-Lys-Thr-Cys)-Nal-NHis also disclosed.

Method of modulating the proliferation of medullary thyroid carcinoma cells

The invention features somatostatin antagonists having a D-amino acid at the second residue.

Somatostatin antagonists

This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.

Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use

The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A-A-A-Gly-Ser-A-Phe-Leu-A-A-A-A(SEQ ID NO: 93), wherein each of A, A, and Ais independently absent, an amino acid, or an amino protecting group; each of A, A, A, and Ais independently absent or an amino acid; and Ais a serine conjugated with a &#x2014;(O)C-Calky or a diaminopropionic acid conjugated with a &#x2014;C(O)C-Calkyl group, provided that at least one of A, A, or Ais present.

The present invention provides novel compounds that have been demonstrated to be modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, iso forms and variants thereof). These compounds are useful as antagonists of the ghrelin receptor as well as inverse agonist, partial agonist or a combination of these activities as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, diabetes, central nervous system disorders, genetic disorders, and hyperproliferative disorders.

Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof

The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful for treating and preventing a Flavivirus invention. Pharmaceutical compositions comprising the peptides, and methods of treating or preventing Flavivirus infections, are also provided.

Flavivirus fusion inhibitors

The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The present invention is based in part on the discovery that E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by Flaviviruses.

The invention features conjugates of therapeutic or cytotoxic agents and biologically active peptides and methods of use thereof.

Conjugates of therapeutic or cytotoxic agents and biologically active peptides

Growing community of inventors

New Orleans, LA, United States of America

David H Coy